WebbMs. Michelle Carpenter, J.D., RAC serves as Chief Regulatory & Clinical Officer at TearSolutions, Inc. (TearSolutions, LLC). Ms. Carpenter has been Vice President of Regulatory Affairs and Project Management at True North Therapeutics, Inc. since April 05, 2024. She served as a Vice President of Regulatory Affairs and Project Management at ... Webb13 feb. 2024 · Charlottesville, Va., February 14, 2024 (Globe Newswire) — Tear Solutions, Inc. (“The Company”), a privately held developer of a replacement therapy for the treatment of dry eye disease (DED) called Lacrip, today announced that it will be partnering with the U.S. Food and Drug Administration (FDA) in late 2024.
Press Release Distribution and Management
WebbCompany Description: Key Principal: Mark Logan See more contacts. Industry: Pharmaceutical and Medicine Manufacturing , Chemical Manufacturing , Manufacturing , … Webb21 feb. 2024 · TearSolutions is part of the Drug Stores & Pharmacies industry, and located in Virginia, United States. TearSolutions Location 315 Old Ivy Way Ste 301, Charlottesville, Virginia, 22903, United States Description Read More Industry Drug Stores & Pharmacies Retail Discover more about TearSolutions Tom Gadek Work Experience and Education jared comenity payment
Tom Gadek - Chief Executive Officer &.. - TearSolutions ZoomInfo
Webb3 aug. 2024 · Lacripep (TearSolutions, Charlottesville, VA) is an investigational synthetic 19 amino acid peptide fragment of lacritin. 1,2 The 19 amino acid synthetic fragment retains all known biologic activity of the full 119 amino acid lacritin monomer 2 . Lacritin was discovered by screening for natural protein agonists of tear secretion in vitro. 1 WebbTearSolutions Inc. 639 följare på LinkedIn. Naturally Restoring Ocular Health TearSolutions Inc. is a Delaware Corporation based in Charlottesville, VA. The company has successfully completed a well-powered 204 patient Phase II Proof of Concept clinical trial for the treatment of the signs and symptoms of dry eye in primary Sjögren’s … Webb10 aug. 2024 · Jens Biertumpel Joins the Board of Directors of TearSolutions, Inc. Oct 27, 2024 Progress in LacripepTM Phase II Trial for Primary Sjogren's Syndrome Dry Eye low fodmap beef broth